Market Place
Sourcing Support
Coya Therapeutics Provides a Corporate Update
16 Mar 2026 //
BUSSINESSWIRE
Coya Therapeutics CEO Sends Letter To Stockholders
20 Jan 2026 //
BUSINESSWIRE
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon
07 Oct 2025 //
PHARMIWEB
Coya Therapeutics Announces Q2 Financial Results and Update
12 Aug 2025 //
PR NEWSWIRE
Coya Therapeutics Updates Progress on Treg-derived Exosome Program
26 Mar 2025 //
BUSINESSWIRE
Coya Therapeutics Reports Fiscal 2024 Financial Results
18 Mar 2025 //
BUSINESSWIRE
Coya Reports Improvement in Inflammatory Markers in Alzheimer
06 Feb 2025 //
BUSINESSWIRE
Coya Therapeutics to Present at Oppenheimer Annual Conference
04 Feb 2025 //
BUSINESSWIRE
Coya Therapeutics Announces Arun Swaminathan as CEO
01 Nov 2024 //
BUSINESSWIRE
Coya reports positive response, safety in mid-stage Alzheimer`s drug trial
29 Oct 2024 //
REUTERS
Coya Therapeutics to Present at Upcoming Healthcare Conferences
03 Sep 2024 //
BUSINESSWIRE
Coya Therapeutics Files New Patents For COYA 301 With GLP-1 Agonists
31 Jul 2024 //
BUSINESSWIRE
Coya Therapeutics Expands Research Collaboration For T Cell Exosome Platform
20 Jun 2024 //
BUSINESSWIRE
Coya Therapeutics Announces ALS Study Publication In Neurology
11 Jun 2024 //
BUSINESSWIRE
Coya`s Manuscript On Neurology Accepted In Frontiers In Neurology
03 Jun 2024 //
BUSINESSWIRE
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
28 May 2024 //
BUSINESSWIRE
Coya Completes Phase 2 Low Dose IL-2 Study In Alzheimer`s
22 May 2024 //
BUSINESSWIRE
Coya Therapeutics Announces $5M Strategic ADDF Investment
20 May 2024 //
BUSINESSWIRE
Coya Therapeutics Q1 2024 Unaudited Financials, Update
09 May 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
22 Apr 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
18 Apr 2024 //
BUSINESSWIRE
Coya Therapeutics Provides a Corporate Update & Reports Fiscal 2023 Results
19 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics Presents ALS Biomarker Data at Conference
12 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics to Participate in BTIG Fireside Discussion
12 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in FTD
06 Mar 2024 //
BUSINESSWIRE
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg)
29 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics to Present Biomarker Survival Data in Large Cohort of ALS
22 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics Licenses Intellectual Property Rights
13 Feb 2024 //
BUSINESSWIRE
Coya Therapeutics Announces Pipeline Expansion of COYA 302
16 Jan 2024 //
BUSINESSWIRE
Mr. Wilbur L. Ross Joins Board of Coya Therapeutics, Inc.
20 Dec 2023 //
BUSINESSWIRE
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
13 Dec 2023 //
BUSINESSWIRE
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
12 Dec 2023 //
BUSINESSWIRE
DRL partners with Coya Therapeutics to develop nerve disorder therapy
07 Dec 2023 //
BUSINESS-STANDARD
Coya Therapeutics Announces $26.5 Million Private Placement
06 Dec 2023 //
PRESS RELEASE
Coya and Dr. Reddy’s Enter into an Exclusive Collaboration
06 Dec 2023 //
BUSINESSWIRE
Coya Therapeutics Reports Q3 2023 Unaudited Financial Results
08 Nov 2023 //
BUSINESSWIRE
Coya Announces Acceptance of Presentation, Regulatory T Cell Expansion Strategy
27 Oct 2023 //
BUSINESSWIRE
Coya Announces Completion of Enrollment in Phase 2 Study of LD IL-2
09 Oct 2023 //
BUSINESSWIRE
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data
03 Oct 2023 //
BUSINESSWIRE
Coya Successfully Engineers Regulatory T Cell (Treg) with CTLA-4 Protein
07 Sep 2023 //
BUSINESSWIRE
Coya Therapeutics Reports Q2 2023 Unaudited Financial Results
08 Aug 2023 //
BUSINESSWIRE
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
03 Aug 2023 //
BUSINESSWIRE
Coya Announces the Appointment of Dr. Merit Cudkowicz as Clinical Advisor
19 Jul 2023 //
BUSINESSWIRE
Coya to Present Proof-of-Concept Clinical Data for Low-Dose Intl-2 (ld IL-2)
28 Jun 2023 //
BUSINESSWIRE
Coya deems dementia drug R&D plan `premature,` switches focus
12 Jun 2023 //
FIERCE BIOTECH
Coya Therapeutics reports positive data from small Alzheimer’s disease trial
16 May 2023 //
CLINICAL TRIALS ARENA
Coya Therapeutics to Present at the Sidoti Virtual Investor Conference
09 May 2023 //
BUSINESSWIRE
Coya Provides Business Update and Reports FY 2022 Unaudited Financial Results
29 Mar 2023 //
BUSINESSWIRE
Coya Therapeutics Appointed Arun Swaminathan, Ph.D. as Chief Business Officer
27 Mar 2023 //
BUSINESSWIRE
Coya to Present at the Virtual Investor Summit on March 29, 2023
23 Mar 2023 //
BUSINESSWIRE
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302
09 Mar 2023 //
BUSINESSWIRE
Coya to Present ALS Study Data for its Investigational Biologic Combination
27 Feb 2023 //
BUSINESSWIRE
Coya Announces Expansion of Worldwide Licensing Agreement with ARScience
15 Feb 2023 //
BUSINESSWIRE
Coya to Present Proof of Concept Data at Multiple Scientific Conferences 2023
02 Feb 2023 //
BUSINESSWIRE
Coya Announces Preclinical Data Supporting Role of Expanded Regulatory T Cells
26 Jan 2023 //
BUSINESSWIRE
Coya debuts in final moment of 2022 with $15M IPO
03 Jan 2023 //
FIERCE BIOTECH
Coya Therapeutics, Inc. Announces Closing of $15.25 M Initial Public Offering
03 Jan 2023 //
BUSINESSWIRE
Coya Therapeutics, Inc. Announces Pricing of $15.25 M Initial Public Offering
29 Dec 2022 //
BUSINESSWIRE
Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a
01 Sep 2022 //
GLOBENEWSWIRE
